Clinical Trials Logo

Colonic Diseases, Functional clinical trials

View clinical trials related to Colonic Diseases, Functional.

Filter by:

NCT ID: NCT01028898 Active, not recruiting - Clinical trials for Irritable Bowel Syndrome

Abnormal Expression Proteins, Mitochondrial DNA and miRNA of Irritable Bowel Syndrome

IBS
Start date: January 2006
Phase: N/A
Study type: Observational

In the investigators study, the investigators will focus on the screening of the related proteins and miRNA to IBS in order to reveal the possible clues or molecular mechanism for this disorder.

NCT ID: NCT00518349 Completed - Carcinoma Clinical Trials

Colonoscope Passive Bending Function

Start date: August 2003
Phase: N/A
Study type: Interventional

A prototype colonoscope with an extra passively bending distal section has been developed by Olympus Japan (ref. publications). The present study (2006-2007) is testing refinements of this function.

NCT ID: NCT00213317 Completed - Fecal Incontinence Clinical Trials

Effect of Lumbo-sacral Magnetic Stimulation on Colonic Motility

Start date: April 2005
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate the effect of sacral nerve magnetic stimulation on the colonic motility in healthy subjects, in incontinent and constipated patients.

NCT ID: NCT00189033 Completed - Clinical trials for Colonic Diseases, Functional

Dietary Interventions in Irritable Bowel Syndrome: Soluble, Insoluble or no Fibre?

Start date: April 2005
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the role of dietary fibre in Irritable Bowel Syndrome (IBS) treatment, in particular the role of increasing the content of soluble or insoluble fibres in the daily diet. The primary objective is to compare soluble (psyllium) and insoluble (bran) to placebo, administered over 12 weeks in patients with ‘probable’ or ‘definite’ Irritable Bowel Syndrome. The primary efficacy parameter is the responder rate based on weekly assessment of adequate relief of IBS symptoms. Secondary efficacy parameters include changes in IBS related symptoms (abdominal pain, bowel habits) and quality of life.

NCT ID: NCT00153751 Completed - Clinical trials for Colonic Diseases, Functional

The Efficacy of Herbal Medicine in Relieving Symptoms and Change of Quality of Life of Patients With Irritable Bowel Syndrome (IBS)

Start date: September 2005
Phase: Phase 2
Study type: Interventional

To test the efficacy of herbal medicine in relieving symptoms and change of quality of life of patients with IBS.

NCT ID: NCT00130741 Completed - Clinical trials for Colonic Diseases, Functional

Combination Herbal Therapy (CHT) Versus Placebo in Patients With Irritable Bowel Syndrome (IBS)

Start date: July 2005
Phase: Phase 1
Study type: Interventional

This is an 8-week double-blind, placebo-controlled, randomized, parallel-group study with an additional two week baseline observation period to evaluate the safety of combination herbal therapy (CHT) versus placebo and short and long-term efficacy in terms of improved IBS, overall quality of life (QOL) and symptomatology.

NCT ID: NCT00006157 Completed - Clinical trials for Irritable Bowel Syndrome

Treatment of Functional Bowel Disorders

Start date: July 1996
Phase: Phase 3
Study type: Interventional

The primary purpose for this study is to compare clinical treatments for patients with functional bowel disorders (irritable bowel syndrome, abdominal pain, painful constipation) in women. We also plan to: 1) determine what clinical features (medical or psychological) determine which patients will improve to these treatments, and 2) understand if there are any physiological features that relate to improvement in symptoms and response to the treatments. We will compare a psychological treatment (cognitive-behavioral therapy - CBT) with education/attention placebo, and an antidepressant drug (desipramine) with a pill placebo. This is the first large-scale study designed to determine the therapeutic effects of these methods, and to also determine interactions among physiologic measures, psychologic and sociodemographic factors, severity of symptoms, and therapeutic improvement including quality of life.